MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/13543784.2025.2500292

Медицинская библиотека · Expert opinion on investigational drugs · 2025

Assessing the clinical progress of the bispecific nanobody sonelokimab.

Dogra Sunil, Singh Sukhdeep

СтатьяОбзорПеревод в очереди

Аннотация

INTRODUCTION

Sonelokimab, a bispecific nanobody targeting interleukins (IL)-17A and IL-17F, has emerged as a novel therapeutic candidate for chronic inflammatory diseases, such as psoriasis, hidradenitis suppurativa (HS), and psoriatic arthritis. Its innovative design offers improved tissue penetration, rapid clearance, and reduced immunogenicity, addressing limitations of current monoclonal antibody therapies.

AREAS COVERED: This review evaluates the pharmacodynamics, pharmacokinetics, clinical efficacy, and safety profile of sonelokimab, drawing from data obtained in phase 1 and 2 trials. Key findings highlight its superior performance in disease-specific indices such as the Psoriasis Area and Severity Index (PASI) and Hidradenitis Suppurativa Clinical Response (HiSCR). A favorable safety profile with common adverse effects like nasopharyngitis, pruritus, headache have been reported.

EXPERT OPINION: Sonelokimab's dual inhibition of IL-17A and IL-17F provides enhanced efficacy over single-target therapies. Its nanobody-based structure enables deeper tissue penetration and better disease control. Further phase 3 trials and head-to-head studies are crucial to establish its long-term efficacy and safety, potentially positioning it as a leading therapeutic option.

Для цитирования: Dogra Sunil, Singh Sukhdeep. Assessing the clinical progress of the bispecific nanobody sonelokimab.. Expert opinion on investigational drugs. 2025. DOI: 10.1080/13543784.2025.2500292.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.